ORIC PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $149.00K, a 338.24% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.25M, a 394.86% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $749.00K, a 494.44% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $34.00K, a 88.40% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.98M, a 213.63% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $631.00K, a 969.49% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $59.00K, a 25.32% decline from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $79.00K, a 91.99% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $149.00K 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $1.25M 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $1.98M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $749.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $34.00K 10-Q · filed 2026-08-03 | |
| 2025-03-31 | $253.00K 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $631.00K 10-K · filed 2026-02-23 | |
| 2024-09-30 | $126.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $293.00K 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $198.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $59.00K 10-K · filed 2025-02-18 | |
| 2023-09-30 | $31.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $79.00K 10-K · filed 2024-03-11 | |
| 2022-09-30 | $1.00K 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $61.00K 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $16.00K 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $986.00K 10-K · filed 2023-03-16 | |
| 2021-09-30 | $99.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $58.00K 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $16.00K 10-Q · filed 2022-11-07 | |
| 2020-12-31 | $443.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | $53.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $39.00K 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $12.00K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $131.00K 10-K · filed 2022-03-21 | |
| 2019-03-31 | $21.00K 10-Q · filed 2020-05-20 | |
| 2018-12-31 | $79.00K 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |